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 2 
Introduction 
 
Myopia is one of the leading causes of visual impairment in the world especially from 20-50 years 
of age.
1
 Prevalence rates of myopia vary between 2 and 33%, depending on the race and age of the 
analyzed population.
2-11
 The prevalence of myopia has been reported to reach 1.7% to 2.1% of the 
general population of United States,
9
 but is higher in Asia and Middle East
10-12
  
Myopia can be classified as simple (physiologic) and degenerative (or pathologic). Eyes with 
simple myopia have a refractive error of less than 6 diopters, and lack pathological changes, 
whereas eyes with degenerative myopia  present a refractive error of at least 6 diopters in 
association with degenerative changes occurring especially in the posterior segment of the globe.
 3-6
 
The pathogenesis of degenerative myopia is still unclear, but both hereditary and environmental 
factors seem to play a role. Degenerative myopia (DM) may be determined by genetic factors to a 
greater extent than simple myopia and the genetic profile of degenerative myopia might differ from 
that of simple myopia. 
Multiple loci for susceptibility to myopia have been mapped, most of which are autosomal 
dominant.
13
 These loci include MYP3 (603221) on 12q, MYP5 (608474) on 17q, MYP6 (608908) 
on 22q12, MYP7 (609256) on 11p13, MYP8 (609257) on 3q26, MYP9 (609258) on 4q12, MYP10 
(609259) on 8p23, MYP11 (609994) on 4q22-q27, MYP12 (609995) on 2q37.1, MYP14 (610320) 
on 1p36, MYP15 (612717) on 10q21.1, MYP16 (612554) on 5p15.33-p15.2, MYP17 (formerly 
MYP4) (608367) on 7p15, MYP19 (613969) on 5p15.1-p13.3, and MYP20 (614166) on 13q12.12. 
An autosomal recessive locus, MYP18 (255500), maps to 14q21-q24.  X-linked loci include MYP1 
(310460) on Xq28 and MYP13 (300613) on Xq23-q25. 
Furthermore, DM occurs commonly in association with Marfan, Ehlers-Danlos, Down and Sticklers 
syndromes. 
Environmental factors include close work, emotional stress, and increasing formal education. 
Prolonged  accommodation and intraocular pressure are suspected of influencing axial elongation in 
eyes with decreased scleral  resistance.
14-17 
    
Many factors including scleral growth and remodelling, along with vitreous synthesis might be 
involved in the development of myopia.
17-20
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Choroidal Neovascularization 
 
A major cause of visual loss in myopic eyes is the development of choroidal neovascularization 
(CNV). The prevalence of  CNV has been reported between 5% and 10%,
21-22
 with subfoveal 
location being quite frequent, accounting for 58-74% of cases, whereas juxtafoveal CNV has been 
described in 32% of cases.
2
 Myopic CNV are generally small (< 1 disc area), flat, greyish with 
hyperpigmented margin. Most of CNV are less than 1000μ in diameter,23 perhaps in relationship 
with the underlying attenuation of the blood supply from the thinner choroid. Moreover, myopic 
CNV are type II ( located in the subretinal space between the sensory retina and the retinal pigment 
epithelium) in most cases, as opposed to CNV associated with age-related macular degeneration, 
which  are mostly type I (situated in the sub-retinal pigment epithelium space).
24,25
 CNV may occur 
adjacent to a lacquer crack, in an area of geographic atrophy of the retinal pigment epithelium 
(RPE), or also in an area of generalized attenuation of RPE and choroid.
25
 Among myopic patients 
with pre-existing CNV, more than 30% will develop CNV in the fellow eye within 8 years.
26
 
Fluorescein angiography (FA) may demonstrate abnormally slow choroidal and retinal blood flow 
in myopic patients and is helpful in identifying and locating the site of choroidal neovascularization. 
Characteristic pattern of myopic CNV is an early hyperfluorescence, with little to moderate leakage 
in the late phases. In particular, myopic CNV shows a minimal or absent leakage not exceeding the 
border of the lesion in 77% to 96% of cases.
24-26 
 
 
 
Natural History of CNV 
 
Previous reports about the natural history of myopic CNV have been conflicting, because this kind 
of lesion has been often reported to have a relatively self-limiting course in the short-term follow-
up. Even though the short-term visual prognosis may be relatively good, long-term visual outcome 
is frequently poor. A recent survey showed that visual acuity does not significantly change during 
the first 3 years from CNV onset, but gets worse after 5 years.
27
 Nevertheless, visual acuity at 5 
years after the onset of CNV decreased to ≤20/200 in 89% of the eyes and in 96% of the eyes after 
10 years.
28
 The long-term bad prognosis related to myopic CNV has been recently confirmed by 
another survey.
29
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Treatment of CNV  
 
Laser photocoagulation has been successfully applied in extrafoveal and juxtafoveal CNV.
30-32
 A 
randomized controlled trial employing krypton red laser photocoagulation demonstrated that 40% in 
the treated group compared to 13% in the observed group had a visual acuity improvement of at 
least 2 lines.
32
  Rate of CNV recurrence was high, reaching the value of 31.4% of cases, especially 
during the first 12 months of follow-up.  Another important concern regarding laser 
photocoagulation of CNV is the expansion of the atrophic scar, especially towards the myopic 
crescent, which happens in 92-100% of cases and can bring about a severe visual deterioration 
when involves the foveal centre.
30,32,33
 Laser photocoagulation is not indicated when CNV has 
subfoveal location, in order to avoid the damage of the foveal centre, and other therapeutic options 
including surgical approach and photodynamic therapy. Surgical interventions are comprised of 
surgical removal of CNV and macular translocation. Surgical removal of CNV has been reported to 
be able to improve visual acuity in a variable number of patients, but is burdened with a recurrence 
rate varying from 18% to 57%, with possible expansion of RPE atrophy.
 35-37
 The rationale of 
macular translocation is to displace sensory retina originally lying over the subfoveal CNV onto a 
health RPE. Limited macular translocation has the advantage of less tissue manipulation, but has the 
disadvantage of less foveal displacement in comparison to macular translocation with 360
0
 
retinotomy. Overall, it seems that best long-term results may be achieved by means of macular 
tanslocation with 360
0
 degree retinotomy.
36-38
  Macular translocation surgery may be associated 
with severe complications including retinal detachment, proliferative vitreoretinopathy, macular 
hole, and corneal astigmatism.  
VIP trials have demonstrated that photodynamic therapy with verteporfin is effective in retaining 
quality of vision by stabilizing or improving visual acuity and contrast sensitivity.
 39,40
 In particular, 
the median visual acuity was stable in the verteporfin-treated group, whereas patients in the placebo 
group lost almost 2 lines after the first year of follow-up. Such a benefit was maintained at 24 
months when the median visual acuity of the treated and the placebo patients had changed from 
baseline by +0.2 lines and -1.6 respectively. Overall, vision turned out to be improved of at least 1 
line from baseline at month 24 in 39% of verteporfin-treated patients compared with 13% of 
controls;  an improvement of at least 3 lines was noted  in 12% of treated patients as opposed to no 
placebo-given patient. 
Photodynamic therapy with verteporfin has been found beneficial also for patients presenting 
recurrent CNV after thermal laser treatment.
41
  
 5 
Typical aspects of photodynamic therapy for CNV in degenerative myopia are the absence of the 
hypofluorescent ring surrounding the CNV and the possible early bridging of multiple foci of 
CNV.
42
   
 
 
 
Anti-VEGF Treatment 
 
The advent of anti-vascular endothelium growth factor (VEGF) treatment has completely changed 
the current management of degenerative myopia-related CNV. Many studies have clinically showed 
that anti-VEGF approach can halt the progression of the myopic CNV, promoting a variable visual 
acuity improvement.
43-62
 
The rationale on the basis of anti-VEGF therapy is related to the histopathological evidence that 
myopic CNV can express VEGF and that VEGF aqueous level in eyes hosting myopic CNV can be 
reduced after intravitreal injection of bevacizumab 
63-64
 Moreover, many practical experiences have 
been reported describing the positive effects of anti-VEGF approach for CNV related to DM on FA, 
optical coherence tomography (OCT), and clinical features. Overall, all the published clinical trials 
markedly differ regarding the characteristics of CNV included, the length of follow-up, the 
treatment regimen selected, the molecule injected. Moreover, most of the studies included subfoveal 
myopic CNV. 
Therefore, many questions are still opened regarding the most appropriate management of CNV 
secondary to DM. In particular, very limited data are currently available regarding the long-term 
effects of anti-VEGF approach. Furthermore, there is no clear indication for the best anti-VEGF 
molecule, the best treatment regimen, and the best monitoring procedure over the follow-up. Lastly, 
limited data are available concerning the anti-VEGF treatment effects for non-subfoveal myopic 
CNV. 
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Long-term Effects of anti-VEGF therapy for subfoveal myopic CNV  
 
In an attempt to assess the effects of intravitreal bevacizumab in the treatment of subfoveal myopic 
CNV in the long-term, we designed an open-label, prospective, clinical trial.
60
 Thirty eyes with 
treatment-naive subfoveal myopic CNV were included and followed-up. Best-corrected visual 
acuity (BCVA) on Early Treatment Diabetic Retinopathy Study (ETDRS) charts, fluorescein 
angiography (FA), and OCT were performed at baseline and, thereafter, monthly for 24 months.  
Intravitreal bevacizumab was administered on an as-per-needed basis. Additional injections were 
administered in cases having any of the following: persistent dye leakage on FA, detection of any 
type of fluid on OCT, or presence of a new subretinal hemorrhage on biomicroscopic fundus 
examination.  
Resolution or cessation of CNV activity on OCT was defined as the absence of SRF/IRF, whereas 
resolution or CNV closure on FA was defined as the absence of leakage.  
Primary outcome measures included the change in mean BCVA and the proportion of eyes 
improving by three lines or greater.  
Secondary outcome measures included the change in mean central macular thickness on OCT and 
the proportion of eyes with resolution of intraretinal/subretinal fluid on OCT and leakage on 
fluorescein angiography over the follow-up. A correlation between final BCVA and CNV duration 
was also calculated. 
Mean BCVA improved from 54.8 ± 14.8 (ETDRS letters ± SD) to 59.03 ± 17.0 at 3 months, 
subsequently stabilizing to 58.63 ± 18.52 at 12 months and 59.25 ± 20 at 24 months (Table 1). A 
statistically significant difference was detected only at the 1-month examination. BCVA at 24 
months showed a 3-line improvement in 36.6% of cases and at least a 1-line increment in 43.3% of 
cases (Table 2). Mean central macular thickness (CMT) showed no significant reduction from 
baseline (216.8 ± 86 mm) up to the end of 24 months (205 ± 77.8 mm). At the last visit, a complete 
CNV closure was obtained in 93% of cases while intraretinal/subretinal fluid was detected on OCT 
in 13% of cases.  
The mean number of intravitreal bevacizumab injections was 4.73 (range, 1–10) at the end of 12 
months and 5.9 (range, 1–13) at the end of the 24 months. No negative side-effects were registered 
over the follow-up. In addition, regression analysis between the change in mean BCVA over 24 
months and the duration of the disease before the treatment by anti-VEGF confirmed that the early 
treatment offers the greater chance of maintaining or improving the visual function. 
 7 
This study with intravitreal bevacizumab as anti-VEGF molecule for naive subfoveal myopic CNV 
reveal positive results in the long-run, with visual improvement in about 1/3 of eyes and 
stabilization in about 2/3 of eyes.  
 
 
 
Best Treatment Drug: Bevacizumab vs Ranibizumab 
 
Only recently the first randomized comparative clinical trial evaluating the efficacy and safety of 
bevacizumab versus ranibizumab for the treatment of CNV secondary to DM has been published by 
Gharbyia et al.
55
 At 6-month examination, endpoint of the study, no difference in the efficacy of 
ranibizumab versus bevacizumab could be demonstrated. Ranibizumab group and bevacizumab 
group achieved a comparable improvement in the BCVA of  3.4 and 3.0 lines, respectively, and 
both drugs were similarly effective in reducing the retinal thickness. These results are consistent 
with the existing data of recent studies on ranibizumab, which have 12 months of follow-up and 
show visual improvement from 1.5 to 3 lines, with about one quarter of subjects gaining at least 3 
lines of BCVA. 
51-54
 Similarly, studies employing bevacizumab achieved a visual improvement 
between 1.9 and 3 lines, with 70% of subjects gaining more than 1 line. 
43-50
 
In an attempt to assess if any treatment effect is related to a specific anti-VEGF molecule, we 
designed a prospective randomized interventional study in order to compare intravitreal 
bevacizumab (IVR) and ranibizumab (IVR) in the treatment of subfoveal myopic CNV. 
Forty-eight patients affected by subfoveal myopic CNV were randomized either to IVB or IVR. Re-
treatments were performed on a pro-re-nata basis in monthly examinations over a 18-month follow-
up. The primary outcome measures were the change in mean BCVA, and the proportion of eyes 
improving in BCVA by  > 1 and > 3 lines at the 18-month examination. Twenty-five eyes 
underwent IVB, and 23 received IVR.  
BCVA on ETDRS charts, FA, and OCT were performed at baseline and, thereafter, monthly for 18 
months. All intravitreal injections were administered on an as-per-needed basis. After the first 
treatment, further re-treatment were performed when the following features were identified: 
persistent dye leakage on FA, detection of any type of fluid on OCT, or presence of a new 
subretinal hemorrhage on biomicroscopic fundus examination.  
Resolution or cessation of CNV activity on OCT was defined as the absence of SRF/IRF, whereas 
resolution or CNV closure on FA was defined as the absence of leakage.  
 8 
At baseline, the mean BCVA values were 0.59±0.32 in the IVR and 0.61±0.28 in the IVB groups 
(Table 3). At 1-month examination, BCVA showed a statistically significant improvement in both 
groups with a mean value of 0.42±0.37 and 0.53±0.27, in the IVR and IVB groups respectively 
(Figure 2). A positive trend was subsequently preserved over the entire follow-up.  
In comparison to the baseline, a statistically significant improvement in BCVA was observed at the 
18-month examination, with a final mean BCVA of 0.40 ± 0.38 and 0.44 ± 0.32  in the IVR and 
IVB groups respectively. No statistically significant difference was observed between the IVR and 
IVB groups over the entire follow-up with respect to the BCVA. At the end of the 18-month follow-
up, a significant improvement of 1.7 lines and 1.8 lines compared to baseline were noticed in IVR 
and IVB subgroups, respectively. 
A 3-line gain or higher was noted in 30% of eyes in IVR subgroup and 44% of eyes in IVB 
subgroup with no statistically difference in the proportion between the two groups (Table 4). 
With regard to CMT, the IVR group showed a statistically significant (p=0.002) reduction from 1-
month examination on (192± 98µm) in comparison to the baseline value (257±96µm). On the other 
hand, the IVB group achieved a statistically significant reduction (p=0.005) in mean CMT 
compared to the baseline value (218±64µm) only at the 3-month examination (183±69µm)(Figure 
3).  
Post-treatment FA and OCT analysis performed at 18-month examination revealed that in the IVR 
group a complete suspension of CNV activity was recognized in 100% of subjects. In the same 
specific time point, 4 eyes (16%) in the IVB group showed leakage on FA or SRF/IRF on OCT. 
 A significantly lower number of injections were administered in IVR subgroup (2.5±1.6) compared 
to IVB subgroup (4.7±2.2) (p<0.001).  
Thus, both IVR and IVB turned out to be effective in the therapy of subfoveal myopic CNV. Both 
molecules achieved similar visual outcomes, even though IVR showed a slightly greater efficacy in 
terms of the mean number of injections and CNV stabilization.  
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Effects of Treatment Regimen  
 
The treatment regimen used in the management of myopic CNV includes two main protocols:  the 
pro-re-nata regimen and the treatment with loading phase followed by monthly injections or by 
three consecutive injections. Overall, the PRN regimen is attractive because it attempt to block the 
CNV’ growing by administering fewer injections and reducing in parallel the risk deriving from 
procedure, e.g. retinal break, infection or retinal detachment. In fact, the PRN regimen is the 
protocol mainly adopted in the current clinical practice. Although, no RCT has been carried out to 
compare the efficacy and safety of the two protocols, the functional and anatomical outcomes seems 
comparable. Recently, Ruiz-Moreno et al published two retrospective, non-randomized, multicentre 
studies on large case series comparing the two regimens over 1-year of follow-up and using 
intravitreal bevacizumab. A similar and statistically significant improvement in the BCVA and in 
the central foveal thickness were noted in both groups during the course of the study with no 
difference between the two groups.
65-66
 
 
In an attempt to cast some light on this topic, we designed a prospective clinical trial comparing 
eyes receiving the loading phase vs eyes undergoing from the beginning PRN treatment. 
30 patients referred for subfoveal CNV related to PM from July 2007 to January 2009 were 
prospectively enrolled in the study. At baseline each patient underwent a complete 
ophthalmological examination, including BCVA assessment on standard ETDRS LogMAR charts 
at 4m, slit lamp examination, tonometry, dilated fundus examination, FA and OCT examination. FA 
was performed using scanning laser ophthalmoscopy (HRA, Heidelberg, Germany) at the baseline, 
at 1 and 3-month examination and subsequently in a quarterly basis. Additional FA was performed 
whenever OCT was questionable. Re-treatments criteria included detection of any type of fluid on 
OCT, presence of new subretinal haemorrhage on biomicroscopy and/or presence of leakage on FA. 
At 1-month examination, eyes presenting signs of CNV activity received 2 monthly consecutive 
additional IVRI and completed the loading phase.  
According to this re-treatment algorithm, the patients were categorized into two subgroups: eyes 
showing complete resolution of CNV activity at 1-month examination and receiving a single 
injection plus pro-re-nata regimen (PRN Group);  eyes with active myopic CNV at 1 month and 
receiving a complete loading phase of three consecutive injections followed by a pro-re-nata 
regimen (LOAD+PRN Group). 
Twenty-seven patients completed the planned visit over the 18-month of follow-up. Fifteen patients 
were included in the PRN Group and 12 were included in the LOAD+PRN (Table 5). 
 10 
At the baseline, the mean BCVA values were 0.75 ± 0.28 (LogMAR+SD) and 0.73 ± 0.27 in the 
PRN Group and LOAD+PRN Group, respectively (Table 6). At 1-month examination, the BCVA 
showed a statistically significant improvement in both groups. Subsequently, the PRN Group 
showed a further improvement to 0.48±0.28 at 3 months and thereafter a statistically significant 
BCVA gain was preserved  up to the end of the study with a mean final value of 0.47±0.29. On the 
other hand, the LOAD+PRN Group failed to maintain the initial statistically significant 
improvement and a substantial stabilization was observed from the 3-month examination on with a 
mean final value of 0.63±0.36. No statistically significant difference was observed between the two 
groups over the whole follow-up with respect to the BCVA.  
At the end of 18 months, 58% and 25% of eyes in the LOAD+PRN group and 86% and 73% of the 
PRN Group showed a BCVA improvement of >1 and > 3 lines, respectively (Table 7). Five eyes 
(49%) and 1 eye loss >1 and >3 lines in the LOAD+PRN group, respectively. Only 1 eye in the 
PRN Group loss 1 single line. Considering the central macular thickness (CMT) and the greatest 
linear dimension (GLD), a meaningful anatomical improvement was noted at 1-month visit and in 
each scheduled examination in comparison to the baseline values in both groups (Table 8). 
However, whereas the CMT values were comparable in both groups at the baseline and in all 
following visits, the two groups differed significantly in the GLD over the whole follow-up with the 
greater values registered in the LOAD+PRN group (Table 9). 
The mean number of injections administered at the end of follow-up were 1.3±0.5 and 4.4±1 in the 
PRN Group and in the LOAD+PRN Group, respectively. Five patients (33%) in the PRN Group 
received 1 additional injection during the first six months of follow-up. Over the following 12 
months no patient required additional injection. In the LOAD+PRN Group, 10 patients (83%) 
required additional injections over the following months with 5, 3 and 2 eyes requiring 1, 2 and 3 
additional injections, respectively. Only by the fifteenth month, no eyes required additional doses. 
No significant ocular or systemic adverse effects were registered over the course of the follow-up in 
both groups. 
Post-treatment analysis at 18-month examination evidenced that the two groups presented a baseline 
statistically significant differences with regard to mean age, GLD of the CNV, time interval from 
symptoms onset. 
All baseline data including time interval between symptoms onset and diagnosis, baseline BCVA, 
CMT, GLD and age  were combined in a multiple stepwise regression analysis in order to evaluate 
the predictor variables on the final BCVA values. 
 11 
The parameters age (p: 0.01) and baseline BCVA (p: 0.001) were identified as the explanatory 
variable. Specifically, older patients with lower baseline BCVA showed the lower chance of 
obtaining a visual acuity recovery. 
The question of the optimal dose and treatment regimen in myopic CNV management is not 
completely resolved. There is no unequivocal evidence suggesting PRN treatment is more effective 
than a loading phase followed by an as-needed variable dosage regimen. 
In the current study, the two dosing treatment regimens achieved a similar effect in BCVA 
improvement. According to our protocol and considering that in a high percentage of cases 1 or 2 
injections are sufficient for stabilizing the neovascular lesion, the loading phase may be reserved to 
CNV with high activity and showing persistent leakage on FA or OCT subsequently to the first 
injection. 
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Effects of myopic CNV location 
 
As previously stated, in studies with at least 1 year follow-up a significant improvement in the 
visual acuity may be encountered in eyes with subfoveal myopic CNV receiving intravitreal 
bevacizumab or ranibizumab.  
There are only few investigations regarding the effect of therapy with anti-VEGF in CNV with 
extrafoveal and juxtafoveal location. Ikuno et al recorded a positive outcome of intravitreal 
bevacizumab in a prospective study on a large series of patients with myopic CNV including eyes 
with subfoveal (43%), juxtafoveal (49%) and extrafoveal (8%) CNV.
47
 However, the authors did 
not specify the visual acuity values associated with the 5extrafoveal CNV cases and the 31 
juxtafoveal CNV cases. Most of the other surveys considered in the population study subfoveal and 
juxtafoveal CNV and did not provide a subgroup analysis. Thus, limited data are available in the 
current literature about the effect of anti-VEGF treatment for non-subfoveal CNV. 
We have analyzed the effects of the intravitreal therapy for juxtafoveal and extrafoveal myopic 
CNV in two different investigations, obtaining interesting results. 
 
Juxtafoveal myopic CNV 
 
The effects of anti-VEGF treatment for juxtafoveal myopic CNV was determined by means of a 
prospective randomized clinical investigation, comparing the visual acuity outcomes of laser 
treatment (LT), photodynamic therapy (PDT) with verteporfin, and intravitreal bevacizumab (IVB) 
in patients with juxtafoveal choroidal neovascularization secondary to DM. 
Fifty-four patients were randomized to PDT, LT, or IVB injection (Table 10). IVB subgroup 
received 1.25 mg of IVB at baseline, and re-treatments were performed if persistent intraretinal or 
subretinal fluid evaluated on OCT, or if CNV leakage was detected on FA. PDT subgroup received 
treatment following the Verteporfin in Photodynamic Therapy Study Group guidelines. LT 
subgroup was submitted to direct LT and received PDT treatment if subfoveal CNV recurrence or 
progression was detected on fluorescein angiography. 
Primary outcome measure was considered the change in BCVA at the end of the 2-year follow-up; 
secondary outcomes was proportion of eyes developing a foveal involvement. 
The mean BCVA decreased in the PDT subgroup from 0.52±0.24 (LogMAR) at baseline to 
0.72±0.25 at the end of the study (P=.002) (Table 11).  
LT subgroup showed substantial stabilization from mean baseline BCVA (0.45±0.27) to the 24-
month (0.56±0.34) examination values.  
 13 
BCVA in IVB subgroup increased from 0.6±0.3 at baseline to 0.42±0.35 at the end of the study 
(P=.006). No side-effects were registered over the follow-up. 
Aggiungere proporzione (Table 12) 
During the first year of follow-up CNV recurrence with subfoveal extension were registered in 9 
eyes (53%) in the LT group, which were re-treated using PDT in accordance with the study 
protocol; a foveal extension developed in 13 eyes (72%) of the PDT group. In the bevacizumab 
group 4 patients revealed a CNV foveal extension. Overall, 80% of subfoveal CNV recurrence 
occurred during the first 6 months of follow-up and no subfoveal CNV recurrence were detected in 
the second year. 
In essence, over a course of two years follow-up, a significant improvement in BCVA was 
demonstrated in eyes receiving the bevacizumab treatment whereas the PDT group showed a 
progressive visual acuity worsening and the laser group obtained a substantial stabilization. In 
addition, the IVB lowered the risk of secondary foveal involvement in comparison to laser 
treatment or PDT.  
 
 
 
Extrafoveal myopic CNV 
 
The effects of anti-VEGF therapy for extrafoveal PM-related CNV were analysed through an open 
label, interventional, prospective trial. Fifteen patients affected by extrafoveal myopic CNV were 
treated with IVB injections and followed up 24 months.  
Best-corrected visual acuity (BCVA) assessment on Early Treatment Diabetic Retinopathy Study 
(ETDRS) charts, FA, and OCT were performed at baseline and, thereafter, monthly for 24 months.  
Intravitreal bevacizumab was administered on an as-per-needed basis. After the initial treatment, 
additional injections were administered in cases having any of the following: persistent dye leakage 
on FA, detection of any type of fluid on OCT, or presence of a new subretinal hemorrhage on 
biomicroscopic fundus examination.  
Primary outcome measure were the mean change in BCVA and the proportion of eyes gaining at 
least 3 lines of ETDRS charts at the end of the planned follow-up of 24 months. Secondary 
outcomes included the effect of the IVB on central macular thickness (CMT), size of the CNV, and 
extension to the fovea. 
The mean BCVA changed from 0.47 (logMAR) at baseline to 0.36 (p=0.035) at 1-month 
examination, and to 0.26 and 0.22 at 12- and 24-month examination, respectively (p <0.001). 
 14 
A functional improvement of at least 3 ETDRS lines was achieved by 7 eyes (46.6%) at the 24-
month examination; one eye (6%) showed a BCVA deterioration of 1 line, whereas an improvement 
of 1-2 lines was registered in 7 eyes (46.6%).  
The mean CMT improved from 313±44 µm to 266±61 µm at 1-month examination (p=0.027), to 
263±69 µm at the 12-month examination (p=0.030), and to 254±63 µm at the 24-month 
examination (p=0.008).  
Similarly, mean CNV size decreased from 348±117 µm
2
 at baseline and to 257±114 µm2 after 1 
month (p=0.047), to 259±109 µm2 after 12 months (p=0.048), and to 251±104 µm2 after 24 months 
(p>0.029). 
Finally, IVB prevented a foveal CNV extension in all cases and a mean number of 3 and 3.4 IVB 
injections were administered during the first year and the 2 years of follow-up , respectively. 
 
In essence,  also in eyes with juxtafoveal and extrafoveal CNV secondary to DM, a treatment based 
on intravitreal bevacizumab administration seems lead to a beneficial effect on the visual acuity 
over a 2 years of follow-up avoiding in the most part of patients a secondary foveal involvement. 
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Monitoring procedure: Fluorescein angiography and OCT  
 
In the management of CNV secondary to AMD, the PrONTO study demonstrated that a scheduled 
treatment regimen consisting of a loading phase followed by a monthly treatment administered on 
the basis of specific re-treatment criteria resulted in a functional and anatomical improvement and 
was associated with a lower number of injections compared to a monthly fixed regimen.  Re-
treatment criteria included a loss of five letters or more on a standardized visual acuity chart with 
evidence of any subretinal fluid on OCT, an increase in central retinal thickness of 100 μm or more 
on OCT, any evidence of new hemorrhage; new classic CNV, or detection of fluid on OCT 
persisting 1 month after an injection. 
68-69
 
The analysis of the literature shows that in the clinical practice for the management of anti-VEGF 
therapy in myopic CNV,  most of authors employs as a elective re-treatment criteria the presence of 
intra/subretinal fluid on OCT examination or the evidence of leakage from CNV on fluorescein 
angiography,  without considering the coexisting of a visual acuity loss. Few authors include among 
the re-treatment criteria the loss of visual acuity in absence of a concomitant accumulation of fluid 
on OCT or leakage on FA. Even more rarely, the re-treatment criteria includes the simultaneous 
presence of a visual acuity loss and signs of CNV activity.
44-66
 
These heterogeneous and different approaches probably reflects the lack of information from multi-
center clinical trials able to elucidate and define the treatment guidelines. 
The approach based only on CNV findings lead us to consider an important issue related to monthly 
re-evaluation of CNV activity for deciding the re-treatment. 
Retinal FA is the standard examination for the evaluation of CNV associated to DM. Despite the 
important information provided, FA is burdened by some relatively minor side-effects, including 
nausea, allergic reaction and fever and other more serious ones, such as anaphylactic shock. In 
addition, FA is unattractive because it is unpleasant for the patient, expensive and is more time-
consuming for doctors and assistants.  
For all these reasons, OCT could play a useful role as an imaging technique in view of its non-
invasive nature and more rapid operation. Furthermore, OCT provides ultrastructural morphological 
details not attainable through FA examination.  
However, myopic CNV is not associated with marked signs of exudation, intraretinal oedema, 
neurosensory detachment or retinal pigment epithelium detachment and this could limit the role of 
OCT assessment.
21
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So, while in the management of CNV related to AMD, the OCT examination has shown its value in 
monitoring the activity of the lesion and guiding the re-treatment with anti-VEGF 
68-69
, a similar 
approach has not yet been validated for monitoring CNV activity associated with DM.  
In the absence of clear guidelines on the role of OCT examination, we designed a study to evaluate 
the agreement between FA and spectral domain OCT in detecting the activity of myopic subfoveal 
CNV during treatment with intravitreal bevacizumab injection. 
 
Thirty-four patients with subfoveal myopic CNV eligible to receive IVB injection were 
prospectively enrolled in the study and underwent a complete ophthalmological examination, 
including FA and spectral domain-OCT at baseline and at all planned monthly visits. After the first 
IVB injection, additional re-treatments were performed following detection of fluid on SD-OCT 
and/or presence of leakage on FA. FA and OCT were performed on the same day by two 
experienced, independent examiners masked to the purpose of the study. After carefully 
examination of OCT and FA images, the examiner recorded the signs of CNV activity and the inter-
rater agreement kappa analysis was performed to examine the concordance between FA and SD-
OCT evaluation. Sensitivity and specificity were also calculated. 
At the baseline, the FA and SD-OCT were in agreement in 26/34 cases with a K value of 0.23; 
sensitivity and specificity were respectively 77.4 and 66.7. Of the remaining eight cases, 7 eyes 
presented leakage on FA and absence of fluid on SD-OCT examination, while 1 case showed 
intraretinal fluid on SD-OCT and absence of leakage on FA. At the 1-month examination, 
specificity and K value improved and a concordance was reached in 30/34 cases. At the 3 and 4-
month examination a discordance was noted in six cases. From the 5-month examination on, a 
correspondence was achieved in at least 30/34 cases and reached a perfect match in nine sessions. 
As already stated in previous studies, FA and OCT showed a weak correlation in the diagnostic 
phase, while FA remained the most appropriate examination in order to detect the CNV activity. 
OCT achieved a meaningful agreement with FA during the follow-up phase when CNV activity 
showed a progressive reduction secondary to IVB treatment suggesting that the OCT may play a 
role in monitoring the CNV activity and the re-treatment-related decisions.  
Although an improvement in the agreement between the two methods was observed, we cannot 
assert that this translates into greater reliability OCT examination as indicator of CNV activity. 
It is well known that the myopic CNV is not always associated with intra-or subretinal exudation 
and in confirmation of this feature in the our study the OCT examination did not reveal the presence 
of the retinal fluid in each comparison. 
 17 
The best agreement between the two techniques therefore results only from a greater number of 
inactive cases recognize on FA.  
Considering the morphological features of CNV associated with DM, we recommend caution in 
relying entirely on OCT examination for the assessment of the activity of the neovascular lesion. 
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Conclusion 
 
There is a mounting evidence that the anti-VEGF therapy has assumed a role as first therapeutic 
indication and has modified our approach to the management of therapy for CNV secondary to DM. 
However, the evidence do not derive from multicenter randomized clinical trials but has been 
realized by the efforts of the clinicians in an attempt to modify the natural course of this serious 
complication occurring in the almost 10% of patients affected by PM. 
The final impact of the anti-VEGF therapy on the natural history of myopic CNV is not yet well 
understood. Although the large part of studies reports promising results, it is not yet possible to 
draw definitive recommendations on the most efficacious treatment regimen and protocol, on the 
most appropriate re-treatment criteria and on the most effective drug. In addition, it is unknow 
whether the retinal changes induced by treatment, for example, the perilesional chorioretinal 
atrophy expansion or the formation of marginal cracks can influence negatively the visual function. 
Since it is difficult to imagine the development of a large randomized controlled clinical trial, only 
the combination of information derived from each single study may help us to understand how to 
manage the anti-VEGF treatment in myopic CNV.  
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TABLES 
 
Table 1 
Combined Data of the BCVA and CMT Over the Course of Follow-up 
Characteristic Baseline 1 Month 3 Months 6 Months 12 Months 24 Months 
BCVA in letters 
(mean ± SD) 
54.8 ± 14.8 58.5 ± 14.6 59.03 ± 17 58.0 ± 15.8 58.6 ± 18.5 59.2 ± 20 
P — 0.0089 0.07 0.23 0.15 0.11 
CMT in mm 
(mean ± SD) 
216.8 ± 86 214.5 ± 83 197 ± 89 190 ± 75 209 ± 78 205 ± 77 
P — 0.79 0.07 0.07 0.71 0.57 
A statistically significant improvement in BCVA was registered at the 1-month examination. From 
the 3-month examination on, a stabilization of the mean BCVA values was observed in 
comparison with the baseline value. The mean CMT showed no statistically significant reduction 
from the baseline value up to the end of 24 months 
 
 
 
 
Table 2 
Frequency Distribution of Changes in Visual Acuity from Baseline to 24-Month Examination 
Change in Visual Acuity Number of patients (%) 
≥ 3 lines increase 11 (36) 
≥ 1 line to , < 3 lines increase 4 (13) 
Change between > 1 and < 1 line 5 (16) 
≥ 1 line to , < 3 lines decrease 8 (26) 
≥ 3 lines decrease 2 (6.6) 
By the 24-month examination, one third of patients gained at least 3 lines of BCVA, and another 
one third stabilized their initial BCVA. 
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Table 3 
Baseline characteristics 
Baseline characteristics 
 
Ranibizumab Group 
(n=23) 
Bevacizumab Group 
(n=25) 
p value 
AGE (mean years+SD) 65±13 61±12 >0.05* 
SEX (Female:Male) 18:5 20:5 >0.05+ 
BCVA (mean logMAR±SD)‏ 0.61±0.28 0.59±0.32 >0.05* 
CNV AREA (mean mm3+SD) 1.527±1.190 1.778±1167 >0.05* 
CMT (mean µm+SD) 257±96 218±64 >0.05* 
BCVA: best-corrected visual acuity, CMT: central macular thickness, *: unpaired t test, +: Fisher’s 
exact test 
 
 
Table 4  
Frequency distribution of change in best-corrected visual acuity (BCVA) over 18 months follow-up. 
BCVA (LogMAR) 
Ranibizumab Group 
(n = 23) 
Bevacizumab Group 
(n = 25) 
≥ 3 lines increase 7 11 
≥ 1 line to < 3 lines increase 8 3 
Change between  > 1 and  < 1 line 4 5 
≥ 1 line to < 3 lines decrease 3 6 
≥ 3 lines decrease 1 0 
At the 18-month examination, 30% of the IVR eyes and 44% of the IVB eyes showed a BCVA gain of 
at least 3 lines. Overall, 65% of the IVR eyes and 56% of the IVB eyes gained at least 1 line. The latter 
difference of 11% between the two groups was not statistically significant. In addition, no 
statistically significant difference was noted between the two groups when proportions of eyes 
losing at least 1 or 3 lines were considered 
 
 
 
 21 
Table 5 
Baseline characteristic of patients. 
Baseline 
characteristics 
PRN Group Loading Phase Group P value 
Number of patients 15 12 n.s. 
Mean age 57±9.8 Mean: 68.3±8 0.005 
Gender 10 F / 5 M 9 F / 3 M 0.07 
Mean BCVA (logMAR) 0.75±0.28 0.73±0.27 0.85 
Mean CMT (µm) 337±73 371±111 0.35 
Mean GLD (µm) 1126±387 1784±904 0.017 
Time interval from 
symptoms onset and 
diagnosis (days) 
8.6±4.4 25.8±11 0.0001 
 A statistically significant difference between the two groups was observed with regard to age, 
GLD of CNV, time interval from symptoms onset and diagnosis (days). [BCVA: best-corrected 
visual acuity, CMT: central macular thickness, GLD: greatest linear dimension] 
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Table 6 
Mean changes in the best-corrected visual acuity (BCVA) over the course of follow-up. 
LogMAR BCVA 
(mean + SD) 
Baseline 1 month 3 months 6 months 12 months 18 months 
PRN Group  0.75 ± 0.28 0.54± 0.27 0.48 ± 0.28 0.48 ± 0.28 0.47 ± 0.29 0.47 ± 0.29 
p value  0.0003 0.0001 0.0001 0.0001 0.0001 
Loading Phase 
Group 
0.73 ± 0.27 0.61 ± 0.32 0.60 ± 0.37 0.60 ± 0.36 0.61 ± 0.36 0.62 ± 0.36 
p value  0.002 0.06 0.07 0.14 0.14 
PRN Group vs 
Loading Phase 
Group (p value) 
0.85 0.54 0.32 0.35 0.26 0.26 
A statistically significant improvement in mean BCVA was noted in both groups at 1-month. 
Subsequently, PRN Group preserved a statistically significant increase in the BCVA whereas Loading 
Phase Group showed a substantial stabilization in comparison to the baseline value. No statistically 
significant difference was observed between the two groups over the whole follow-up. 
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Table 7 
Frequency Distribution of Changes in Visual Acuity from Baseline to 18-month examination 
Change in Visual Acuity LOAD+PRN Group PRN Group 
≥ 3 lines increase 3 11 
≥ 1 line increase 7 13 
No change 0 1 
≥ 1 line decrease 5 1 
≥ 3 lines decrease 1 0 
 
 
Table 8 
Mean changes in the central macular thickness (CMT) over the course of follow-up. 
CMT (mean + 
SD) 
Baseline 1 month 3 months 6 months 12 months 18 months 
PRN Group 337 ± 73 262± 85 252 ± 80 241 ± 74 228 ± 56 217 ± 46 
p value  0.005 0.001 0.0005 0.0001 0.0001 
LOAD+PRN 
Group 
371 ± 111 294 ± 103 265 ± 85 282 ± 92 276 ± 100 269 ± 91 
p value  0.009 0.001 0.001 0.001 0.001 
PRN vs 
LOAD+PRN 
Group (p value) 
0.35 0.37 0.68 0.21 0.13 0.06 
A statistically significant improvement in the mean CMT was registered from 1-month examination up 
to the end of 18 months in both groups. No statistically significant difference was observed between the 
two groups during the whole follow-up. 
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Table 9 
Mean changes in the greatest linear dimension (GLD) over the course of follow-up. 
GLD (mean±SD) Baseline 1 month 3 months 6 months 12 months 18 months 
PRN Group 1126 ± 387 993± 368 917 ± 337 878 ± 373 837 ± 368 809 ± 334 
p value  0.001 0.001 0.0008 0.0002 0.0001 
LOAD+PRN 
Group 
1784 ± 904 1670 ± 843 1644 ± 843 1602 ± 823 1559 ± 814 1529 ± 808 
p value  0.007 0.006 0.005 0.005 0.002 
PRN vs 
LOAD+PRN 
Group (p value) 
0.017 0.009 0.009 0.005 0.005 0.004 
A statistically significant improvement in the mean GLD was registered from 1-month examination up to 
the end of 18 months in both groups. A statistically significant difference was observed between the 
two groups during the whole follow-up with the smaller values observed in the PRN Group. 
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Table 10 
Demographic Characteristics of the Patients Randomized to Laser Treatment, PDT, and Bevacizumab 
 
Characteristic 
Laser Treatment 
(17 Eyes) 
PDT 
(18 Eyes) 
Bevacizumab 
(19 Eyes) 
Women, No. (%) 13 (76) 13 (72) 11 (57) 
Mean age, years 44.5 48.1 50.8 
Refractive error, mean, D −10.2 −9.2 −9.6 
Hypertension, No. (%) 2 (11) 2 (11) 1 (5) 
Baseline BCVA,          
mean (SD), logMAR (a) 
0.45 (0.27) 0.52 (0.24) 0.61  (0.3) 
BCVA, best-corrected visual acuity; D, diopters; PDT, photodynamic therapy. 
(a) Best-corrected visual acuity showed no statistically significant difference among the 3 groups at 
baseline. 
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Table 11 
 Change in BCVA During the 24 Months of Follow-up (a) 
Examination, 
mo 
BCVA, logMAR P Value  
PDT LT Bevacizumab LT vs PDT 
Bevacizumab 
vs PDT 
Baseline 0.52 0.45 0.6   
3 0.51 0.46 0.4b   
6 0.49 0.41 0.4b   
9 0.67c 0.39 0.4b <.05 <.05 
12 0.67cd 0.47e 0.4b,f <.05 <.05 
18 0.68c 0.49 0.42b NS <.05 
24 0.72c,d 0.56e 0.42b,f NS <.05 
Abbreviations: BCVA, best-corrected visual acuity; NS, non significant; PDT, photodynamic 
therapy. 
(a)  At baseline, no statistically significant difference was registered among the subgroups. From 
the 3-month examination, a statistically significant improvement of BCVA was recorded in the 
bevacizumab group. At the 1-year follow-up, the PDT group showed a worsening in BCVA, the 
laser treatment group maintained the baseline mean BCVA, whereas only the bevacizumab 
group showed a statistically significant BCVA improvement. At the 24-month examination, a 
worsening in BCVA was registered both in the PDT group (reaching statistically significant 
difference) and in the laser treatment group (without statistically significant 
difference), whereas the bevacizumab group retained its visual improvement. 
(b) Statistically significant improvement in BCVA from baseline in the bevacizumab group from 
the 3-month examination on. 
(c) Statistically significant worsening in BCVA from baseline in the PDT group from the 9-month 
examination on. 
 (d) Statistically significant (P.05) difference compared with baseline (for worsening). 
(e) Statistically non significant difference compared with baseline. 
(f) Statistically significant (P.05) difference compared with baseline (for improvement). 
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Table 12 
Frequency of Mean Changes in Best-Corrected Visual Acuity From Baseline to the 24-Month 
Examination (a) 
 Lines of Gain or Loss, No. (%) of Eyes 
Group <−3 <−1 0 >1 >3 
Photodynamic 
therapy 
8 (44) 13 (72 1 (5.5) 4 (22) 1 (5.5) 
Laser treatment 7 (41) 10 (59) 1 (6) 6 (35) 2 (12) 
Intravitreal 
bevacizumab 
1 (5) 4 (21) 2 (11) 13 (68) 7 (36) 
(a) Stabilization or improvement of best-corrected visual acuity was registered in 27.5%, 41%, 
and 79% of the photodynamic therapy, laser treatment, and bevacizumab groups, respectively 
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Table 13 
 
Sensitivity, specificity and K-value agreement for detecting CNV activity between OCT and FAG 
examination 
Month Sensitivity Specificity 
Kappa 
value 
Number of  
cases  
showing 
complete 
agreemen
t 
Proportion 
of eyes 
showing 
complete 
agreement 
(%) 
OCT+/ 
FAG- 
FAG+/ 
OCT- 
Baseline 77.4 66.7 0.23 26 76 1 7 
1 M 73.3 100 0.75 30 88 0 4 
2 M 69.2 100 0.73 30 88 0 4 
3 M 61.5 95.2 0,60 28 82 1 5 
4 M 62.5 88.4 0,51 28 82 3 3 
5 M 80 100 0,87 33 97 0 1 
6 M 78.5 100 0.81 31 91 0 3 
7 M 87.5 100 0,91 33 97 0 1 
8 M 85.7 92.5 0,74 31 91 2 1 
9 M 77.8 96 0,76 31 91 1 2 
10 M 66.6 100 0,78 33 97 0 1 
11 M 66.6 100 0,78 33 97 0 1 
12 M 71.4 96.3 0.71 31 91 1 2 
13 M 100 100 1 34 100 0 0 
14 M 100 100 1 34 100 0 0 
15 M 100 100 1 34 100 0 0 
16 M 100 100 1 34 100 0 0 
17 M 100 100 1 34 100 0 0 
18 M 100 96 0.92 33 97 1 0 
19 M 100 100 1 34 100 0 0 
20 M 100 100 1 34 100 0 0 
21 M 100 100 1 34 100 0 0 
22 M 100 100 1 34 100 0 0 
23 M 100 87 0.54 30 88 4 0 
24 M 100 94.1 0.63 32 94 2 0 
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FIGURES 
 
Figure 1. Correlation between change in mean BCVA over 24 months and symptom duration before 
treatment with IVB. Overall, an early treatment seems to increase the probability of obtaining better 
stabilization or improvement in visual function. 
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Figure 2:  a statistically significant improvement in BCVA was noted in both groups at the 1- 
month examination. A positive trend was subsequently preserved over the follow-up. At the 
18-month examination a mean improvement of 1.8 lines in the ranibizumab group and 1.7 
lines in the bevacizumab group was registered 
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Figure 3: A statistically significant difference in comparison to the mean baseline CMT was 
registered from the 1-month examination in the Ranibizumab group. A statistically significant 
difference was also observed at the 3- and 6-month visits in the Bevacizumab group;  
at 12 and 18 months, the CMT was shown to have stabilized in comparison with the baseline value.  
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